Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alnylam Pharmaceuticals Inc

Current price
170.04 USD -4.99 USD (-2.85%)
Last closed 175.02 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 21 510 756 352 USD
Yield for 12 month -26.49 %
21.11.2021 - 28.11.2021

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Address: 675 West Kendall Street, Cambridge, MA, United States, 02142


WallStreet Target Price

224.09 USD

P/E ratio

Dividend Yield

2.52 %

Current Year

+1 037 418 000 USD

Last Year

+844 287 000 USD

Current Quarter

+750 530 000 USD

Last Quarter

+318 754 000 USD

Current Year

+868 601 000 USD

Last Year

+704 143 000 USD

Current Quarter

+666 221 000 USD

Last Quarter

+233 384 000 USD

Key Figures ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -299 502 016 USD
Operating Margin TTM 28.5 %
PE Ratio
Return On Assets TTM -6.01 %
PEG Ratio -0.49
Return On Equity TTM -1500.66 %
Wall Street Target Price 224.09 USD
Revenue TTM 1 723 608 960 USD
Book Value -1.32 USD
Revenue Per Share TTM 13.86 USD
Dividend Share
Quarterly Revenue Growth YOY 184 %
Dividend Yield 2.52 %
Gross Profit TTM 868 601 000 USD
Earnings Share -4.11 USD
Diluted Eps TTM -4.11 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -29.58 %

Dividend Analytics ALNY

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 2.52 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 11.8435
Price Sales TTM 12.4801
Enterprise Value EBITDA -71.5982
Price Book MRQ 142.9249

Financials ALNY

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ALNY

For 52 weeks

148.1 USD 242.97 USD
50 Day MA 166.28 USD
Shares Short Prior Month 5 265 151
200 Day MA 188.05 USD
Short Ratio 7.79
Shares Short 5 194 257
Short Percent 5.47 %